Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2017-05-02 Capital/Financing Update
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive inlicensierar ett kliniskt utvecklingsprojekt för genetiska mitokondriella sjukdomar från Yungjin Pharm
Capital/Financing Update Classification · 1% confidence The document announces a global licensing agreement between NeuroVive and Yungjin Pharm for the drug candidate KL1333, detailing financial terms (initial payments, milestones, royalties) and development plans. This type of announcement, concerning corporate transactions, financing, or significant business development (licensing in a clinical asset), fits best under 'Capital/Financing Update' (CAP) as it directly relates to the company's capital structure/assets through a major deal, or potentially 'Regulatory Filings' (RNS) if it were a general disclosure. However, given the specific nature of acquiring rights and associated payments, CAP is a strong candidate. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it details a major transaction involving the acquisition of an asset and associated financial commitments, it is classified as a Capital/Financing Update (CAP). The final sentence mentions the information is subject to EU Market Abuse Regulation disclosure, suggesting it is a mandatory corporate announcement, but the content is transactional, favoring CAP over the general RNS fallback.
2017-05-02 Swedish
NeuroVive in-licenses a genetic mitochondrial disease clinical stage project from Yungjin Pharm
Capital/Financing Update Classification · 1% confidence The document announces a significant corporate action: NeuroVive entering into a global licensing agreement with Yungjin Pharm for a clinical-stage project (KL1333). This involves upfront payments, milestone payments, and royalties, which directly relates to financing activities and capital structure changes concerning the company's assets (drug pipeline). This fits best under 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard regulatory filing (RNS) announcing a routine event; it is a specific announcement about a major transaction impacting the company's future financial structure and assets.
2017-05-02 English
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document explicitly states it contains the "Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)" and details the outcomes of the meeting, such as the approval of financial statements, dividend decision, election of the Board of Directors, and authorization for share issues. This content directly corresponds to the outcomes and materials presented at an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2017-04-27 English
Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is titled 'Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)' (Decisions at the Annual General Meeting in NeuroVive Pharmaceutical AB (publ)) and explicitly states that the Annual General Meeting (årsstämma) was held on April 27, 2017. The content details the decisions made regarding the approval of 2016 financial statements, dividend policy, board member elections, remuneration, guidelines for executive compensation, and authorization for new share issues. These topics are the core components of an Annual General Meeting's proceedings and outcomes. Therefore, the appropriate classification is AGM-R (AGM Information). The document length (5557 chars) is substantial enough to be the actual summary of decisions, not just a brief announcement of a report.
2017-04-27 Swedish
NeuroVive presenterar prekliniska resultat som bekräftar NV556s anti-fibrotiska effekter i NASH
Regulatory Filings Classification · 1% confidence The document is a press release dated April 20, 2017, announcing positive preclinical results for the substance NV556 related to NASH treatment. It details scientific findings, mentions presentation at a medical congress, and includes standard company boilerplate and contact information. Crucially, the final paragraph states: "Denna information är sådan information som NeuroVive Pharmaceutical AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 20 april 2017, kl. 08.00." This structure strongly indicates a mandatory regulatory disclosure, likely related to material non-public information, which often falls under general regulatory announcements or specific press release categories. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific insider trade/dividend notice, the most appropriate general category for a mandatory, time-sensitive regulatory announcement that doesn't fit elsewhere is Regulatory Filings (RNS). It is too detailed to be a simple Report Publication Announcement (RPA).
2017-04-20 Swedish
NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects
Regulatory Filings Classification · 1% confidence The document is a press release dated April 20, 2017, announcing positive preclinical results for the compound NV556 in NASH treatment. It details scientific findings, mentions presentation at a medical congress (The International Liver Congress), and includes standard 'About the Company' and contact information sections. This format is typical of an Earnings Release (ER) or a general corporate update announcing significant, non-financial news. Since it is a detailed announcement of scientific progress rather than a summary of financial performance (ER) or a formal regulatory filing like a 10-K or IR, it best fits the category for general corporate news or scientific updates. Given the options, it is a specific announcement of company progress, which often accompanies or precedes a formal financial report, but here it is a standalone scientific update. It is not a transcript (CT), a formal report (10-K, IR), or a management discussion (MDA). It is most closely aligned with an Earnings Release (ER) if it were financial, but since it is purely scientific/clinical progress, and there is no specific category for 'Scientific Update', it falls under the general category of corporate news releases. However, in the context of financial filings, press releases announcing key operational milestones often substitute for or precede formal financial disclosures. Given the strong focus on presenting new data, it is a significant corporate announcement. Since it is not a report itself but an announcement of findings, and it's not a management change (MANG) or financing event (CAP), the closest fit among the provided options for a major, non-financial corporate announcement is often the 'Earnings Release' category if it's the primary communication vehicle for the period, or 'Regulatory Filings' (RNS) as a catch-all. Since it is a detailed announcement of results, and not just a notice of a report, I will classify it as an Earnings Release (ER) as it communicates the 'results' of their R&D efforts for the period, which is a common practice for biotech/pharma companies when financial results are secondary to clinical milestones. If a 'Press Release' category existed, that would be ideal. Given the choices, ER is the most plausible fit for a major periodic announcement of operational 'results'.
2017-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.